Natural immune suppressor responsible for early death in leukemia patients

Patients diagnosed with the most common form of leukemia who also have high levels of an enzyme known to suppress the immune system are most likely to die early. High levels of this enzyme, indoleamine 2,3 dioxygenase, or IDO, at diagnosis also identify those who might benefit most by taking an IDO inhibitor along with their standard therapy.

A review of patients with acute myeloid leukemia, or AML, found increased IDO expression in the bone marrow biopsy, performed to diagnose their disease, correlated with lower overall survival rates and early mortality. It also indicates that IDO expression should routinely be measured when the diagnostic bone marrow biopsy is performed, Everyone has the IDO gene, it's the cancer cells in this scenario that activate the disabler of the immune response that is also used by the fetus and solid tumors.

 Stem cells in the bone marrow are supposed to mature into a variety of cells that enable human blood and immune system function. Instead in AML, stem cells get stuck in an in-between, undifferentiated state called blasts.In leukemia, stem cells get limboed in the blast state so you don't get any maturation. That means there are low platelets so you get clotting problems, you have low neutrophils so you have infections, you have less red blood cells so you get anemic.

Bleeding is a major cause of death for patients and often, significant gum bleeding is the first indicator. The patients who died at six months had a high expression of IDO while the blasts produced relatively little IDO in the patients who lived five years or more. During pregnancy, cells in the placenta trigger an isolated suppression of the mother's immune system so it won't reject the genetically foreign fetus. They showed that IDO locally disables the mother's immune system by degrading tryptophan, an amino acid essential to survival of T cells , orchestrators of the immune system's response.

Later work would show that tumors - and leukemia - also use IDO to hide from the immune response. Conversely, some organ transplant patients who inexplicably express higher levels of IDO, have lower rejection rates of their new organ. Induction therapy is given to get the patient into remission, and is typically followed by more chemotherapy to ensure it stays dormant.
          haleplushearty.blogspot.com

Fat cells for treating leukemia

Killing cancer cells indirectly by powering up fat cells in the bone marrow could help acute myeloid leukemia patients. Researchers discovered that boosting adipocytes, or fat cells, located in the bone morrow suppressed cancerous leukemia cells.

The production of healthy red blood cells is critical for those with acute myeloid leukemia but is sometimes overlooked as conventional treatments focus on killing the leukemia cells alone. Patients with this disease suffer from anemia and infection due to the failure of healthy blood production.

A drug used to moderate diabetes that induces fat cell production in the bone marrow was used for leukemia patients and was found to help foster red blood cell production as well as suppress leukemic disease.

The drug suppressed the cancer cells and bolstered the healthy cells, allowing them to regenerate in the new drug-induced environment. The drug activates blood regeneration and may provide benefits for those waiting for bone marrow transplants by activating their healthy cells.
        haleplushearty.blogspot.com

Blood cancer destroys bone marrow

Healthy bone marrow stromal
cells were made to transfer their power-generating mitochondria to other cancer cells, effectively feeding the acute myeloid leukaemia AML and supporting the leukaemia to grow.

AML act in a parasitic way by generating oxygen-deprived conditions in the bone marrow which stimulates the transfer of healthy mitochondria from the non-cancerous cells to the leukaemia cells.

An enzyme found in the AML cell membrane was shown to be responsible for creating the conditions necessary for mitochondrial transfer to occur. Researchers established that the enzyme called NOX-2 generated superoxide which drives this transfer.

The transfer takes place through AML-derived tunnelling nanotubes TNTs which link the cancer cells directly to the surrounding healthy cells.
Furthermore by inhibiting NOX-2, researchers showed a reduction in mitochondrial transfer took place which limited how much energy the AML cells could generate and resulted in slower cancer growth.
          haleplushearty.blogspot.com

Mylotarg for treating acute myeloid leukemia

Mylotarg (gemtuzumab ozogamicin) has been approved for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML).

AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream.

Mylotarg is a targeted therapy that consists of an antibody connected to an anti-tumor agent that is toxic to cells. It is thought to work by taking the anti-tumor agent to the AML cells that express the CD33 antigen, blocking the growth of cancerous cells and causing cell death.

Common side effects of Mylotarg are fever, nausea, infection, vomiting, bleeding, low levels of platelets in the blood, swelling and sores in the mouth, constipation, rash, headache, liver damage, and low levels of certain white blood cells.
          haleplushearty.blogspot.com      

Vyxeos for Acute Myeloid Leukemia

Food and Drug Administration has approves Vyxeos (daunorubicin and cytarabine) Liposome for Injection for Certain Types of Poor-Prognosis Acute Myeloid Leukemia

The drug is for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine. Vyxeos combines two commonly used chemotherapies into a single formulation that may help some patients live longer than if they were to receive the two therapies separately.

Acute myeloid leukemia AML is a rapidly progressing cancer that forms in the bone marrow and results in an increased number of white blood cells in the bloodstream. It occurs as a complication of chemotherapy or radiation in patients treated for cancer five years after treatment.

Patients who have a history of serious hypersensitivity to daunorubicin, cytarabine or any component of the formulation should not use Vyxeos.
Patients taking Vyxeos should be monitored for hypersensitivity reactions and decreased cardiac function.

Common side effects of Vyxeos are: hemorrhage, fever with low white blood cell count, rash, swelling of the tissues, nausea, inflammation of the mucous membranes, diarrhea, constipation, musculoskeletal pain, fatigue, abdominal pain, shortness of breath, headache, cough, decreased appetite, abnormal heart rhythm, lung infection, blood infection, sleep disorders and vomiting.
            haleplushearty.blogspot.com